Supplemental material
Oncology
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy
Ivo Abrahama Center for Health Outcomes and PharmacoEconomic Research, University of Arizona, Tucson, AZ, USA;b Department of Pharmacy Practice and Science, College of Pharmacy, University of Arizona, Tucson, AZ, USA;c University of Arizona Cancer Center, University of Arizona, Tucson, AZ, USA;d Matrix45, Tucson, AZ, USACorrespondence[email protected]
https://orcid.org/0000-0003-0490-4421
https://orcid.org/0000-0003-0490-4421, , , Donald Moranf G1 Therapeutics, Inc., Research Triangle Park, NC, USAhttps://orcid.org/0000-0001-7638-0618
https://orcid.org/0000-0001-7638-0618, , Karen MacDonaldd Matrix45, Tucson, AZ, USAhttps://orcid.org/0000-0002-4568-9783
https://orcid.org/0000-0002-4568-9783 & show allRelated Research Data
Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy
Source:
Taylor & Francis
Linking provided by
